HYFT
ImmunoPrecise Antibodies Ltd.
1.50$
-3.2%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.3% | -10.7% | -40.9% | -73.8% | -83.7% | -19.6% | -16.3% | -133.3% | -69.6% | -71.5% | -61.4% | -105.4% | -76.6% | |
| 22.0% | 21.0% | 24.4% | 56.4% | 38.7% | 22.7% | 13.1% | 29.8% | 5.0% | 5.2% | 5.8% | 6.9% | 5.7% | |
| 4.8% | 16.1% | 3.7% | 6.7% | 5.9% | 1.1% | 0.8% | 1.7% | 3.7% | 6.3% | 19.9% | 19.0% | 12.1% | |
| 16.3% | -4.9% | -2.7% | 44.6% | -24.2% | 11.8% | -5.9% | -72.5% | -10.0% | 0.5% | 14.5% | 30.8% | 8.6% | |
| 4.9% | 2.7% | 17.4% | 10.6% | 2.4% | 1.8% | 5.1% | 8.9% | 1.8% | 0.7% | 0.4% | 2.0% | 1.2% | |
| -5.1% | 0.9% | -17.2% | -10.6% | -2.4% | -1.8% | -5.1% | -18.8% | -1.8% | 342.1% | 3.7% | -2.0% | 86.4% | |
| – | – | – | – | – | – | – | -1.5% | -1.9% | – | – | – | – | |
| – | – | – | 89.2% | 39.3% | -2.6% | -6.2% | -10.2% | -2.4% | -2.5% | -6.3% | -4.6% | -3.9% | |
| -5.0% | 9.9% | 17.4% | 109.0% | 77.2% | 171.5% | -6.0% | -11.7% | 341.3% | -319.9% | -6.8% | 9.0% | 6.6% | |
| -11.5% | 3.0% | -42.5% | 18.4% | -14.1% | 152.6% | -31.7% | -182.4% | 281.6% | -46.4% | -68.4% | -105.7% | 17.3% | |
| -5.2% | -8.1% | -58.4% | -84.4% | -86.2% | -21.4% | -21.5% | -142.2% | -71.4% | -72.3% | -61.8% | -107.5% | -77.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.